相关实验视频

Updated: May 6, 2026

Isolation of the Side Population in Myc-induced T-cell Acute Lymphoblastic Leukemia in Zebrafish

Isolation of the Side Population in Myc-induced T-cell Acute Lymphoblastic Leukemia in Zebrafish

Published on: May 4, 2017

TCF3::ZNF384诱导B细胞前体急性淋巴细胞白血病细胞中的类固醇耐药性

Shinpei Kusano^1,2, Hitomi Ueno-Yokohata¹, Momoka Hori^1,3

¹Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Japan.

Pediatrics international : official journal of the Japan Pediatric Society

|May 20, 2025

概括

在B细胞前体急性淋巴细胞白血病 (BCP-ALL) 中ZNF384的重组具有明显的影响. 与EP300::ZNF384不同的是,TCF3:ZNF384赋予了德甲耐药性,并改变了基因表达.

科学领域:

血液学血液学血液学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

ZNF384重组 (ZNF384-r) 定义了特定的B细胞前体急性淋巴细胞白血病 (BCP-ALL) 子组.
TCF3::ZNF384阳性BCP-ALL显示了较差的类固醇反应和高的复发率.
EP300::ZNF384阳性BCP-ALL表现出良好的化疗反应.

研究的目的:

在BCP-ALL中研究TCF3::ZNF384和EP300::ZNF384在BCP-ALL中的独特生物效应.
区分ZNF384重排的聚变合作伙伴依赖的功能.

主要方法:

通过逆转录病毒介导的BCP-ALL细胞系的基因转导与TCF3::ZNF384和EP300::ZNF384.
流式细胞计,RT-qPCR和附件-V结合性亡试验.
氧核酸微阵列分析.

主要成果:

无论是TCF3::ZNF384还是EP300::ZNF384都降低了CD10表达的调节.
TCF3::ZNF384,但不是EP300::ZNF384,增加了对德甲诱导的亡的抵抗力.
TCF3::ZNF384增强了CCND2基因表达,但没有赋予生长优势.

结论:

TCF3::ZNF384 独立于 EP300::ZNF384. 赋予了德克萨米他耐药性.
TCF3::ZNF384表现出超出常见ZNF384-r角色的融合合作伙伴特定功能.
这些独特的功能可能有助于TCF3::ZNF384表达ALL的特定临床特征.

关键词:

EP300::ZNF384 这是一本书.TCF3::ZNF384 这是一个很好的选择.急性淋巴细胞白血病急性淋巴细胞白血病细胞系细胞系的细胞系.类固醇耐药性类固醇耐药性

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...